



# Figure S1




**Figure 1. Characterization of maturation state, infectivity, and mAb neutralization of viral stocks.** (A) Representative Western blot image (left) of DENV1-3 viral supernatants from Vero (V) and Vero-furin cells (VF) stained with anti-E and anti-prM antibodies. (B) Quantification of the increase in maturation state (prM/E) of DENV1-3 virions produced in VF cells compared to Vero cells (lower value = more mature) as seen by relative western blot band intensity. (C) Neutralization potency of monoclonal antibodies (mAbs), with  $EC_{50}$  values in  $\mu\text{g/mL}$  displayed across assay conditions. The darker color corresponds to mAbs with the highest neutralization potency. (D) Relative neutralization potency of mAbs. Values are normalized by the lowest  $EC_{50}$  observed among the four assay conditions (most potent), calculated as  $(1 / (EC_{50} \text{ of assay condition X} / \text{lowest } EC_{50} \text{ of four assay condition}))$ . Large color variation indicates a strong impact of change in assay conditions. Relative  $EC_{50}$  value of 1 (yellow) indicates highest potency, of 0.2 (dark purple) least potent.

## Figure S2



**Figure S2. Cross-reactive nAb titers of pre-inapparent and pre-symptomatic DENV3 infection participants stratified by infection history.** Asterisks indicate Benjamini Hochberg adjusted p-values for the Wilcoxon test. p-values: ns, >0.05; \*, <0.05; \*\*, <0.01; \*\*\*, <0.001; \*\*\*\*, <0.0001.

Figure S3



**Figure S3. Impact of change in assay condition on the nAb response of pre-inapparent and pre-symptomatic infection participants stratified by infection history.** Post-1°: post-primary infection, Post-2°: post-secondary infection. Asterisks indicate Benjamini Hochberg adjusted p.values for paired Wilcoxon tests. p-values: ns, >0.05; \*, <0.05; \*\*, <0.01; \*\*\*, <0.001; \*\*\*\*, <0.0001.